Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Mirum Pharmaceuticals, Inc. Common Stock (MIRM)

Pharmaceutical Preparations

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

950 TOWER LANE, SUITE 1050
FOSTER CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/18/2019

Market Cap

1,959,334,704

Shares Outstanding

46,610,000

Weighted SO

46,614,274

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

IMCR --.--%

LRMR --.--%

KALV --.--%

LYRA --.--%

TERN --.--%

AMLX --.--%

ABOS --.--%

INZY --.--%

XFOR --.--%

Beta

1.1520

Last Div

0.0000

Range

23.14-44.94

Chg

-0.4600

Avg Vol

784503

Mkt Cap

1959334704

Exch

NASDAQ

Country

US

Phone

650 667 4085

DCF Diff

27.6215

DCF

0.7885

Div Yield

0.0000

P/S

7.4112

EV Multiple

-24.4289

P/FV

8.4718

Div Yield %

0.0000

P/E

-18.1891

PEG

-72.9385

Payout

0.0000

Current Ratio

3.2752

Quick Ratio

3.0932

Cash Ratio

2.0768

DSO

83.4302

DIO

105.0050

Op Cycle

188.4352

DPO

50.5656

CCC

137.8697

Gross Margin

0.7313

Op Margin

-0.4007

Pretax Margin

-0.3969

Net Margin

-0.4034

Eff Tax Rate

-0.0165

ROA

-0.1614

ROE

-0.4347

ROCE

-0.1931

NI/EBT

1.0165

EBT/EBIT

0.9905

EBIT/Rev

-0.4007

Debt Ratio

0.4666

D/E

1.3464

LT Debt/Cap

0.5730

Total Debt/Cap

0.5738

Int Coverage

35307.6667

CF/Debt

-0.0760

Equity Multi

2.8855

Rec Turnover

4.3749

Pay Turnover

7.2183

Inv Turnover

3.4760

FA Turnover

26.8130

Asset Turnover

0.4001

OCF/Share

-0.4960

FCF/Share

-0.8304

Cash/Share

5.8933

OCF/Sales

-0.0886

FCF/OCF

1.6740

CF Coverage

-0.0760

ST Coverage

-21.8563

CapEx Coverage

-1.4837

Div&CapEx Cov

-1.4837

P/BV

8.4718

P/B

8.4718

P/S

7.4112

P/E

-18.1891

P/FCF

-49.9550

P/OCF

-82.7975

P/CF

-82.7975

PEG

-72.9385

P/S

7.4112

EV Multiple

-24.4289

P/FV

8.4718

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 11, 13:00 Where Mirum Pharmaceuticals Stands With Analysts Benzinga Dec 19, 13:00 The Latest Analyst Ratings For Mirum Pharmaceuticals Benzinga Dec 19, 07:30 Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga Nov 20, 10:00 11 Analysts Have This to Say About Mirum Pharmaceuticals Benzinga Nov 03, 11:00 Analyst Ratings for Mirum Pharmaceuticals Benzinga Oct 24, 11:00 Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023

Revenue Product Segmentation